The upregulation of FLT3, MYB, DNMT3B, and MYCN oncogenes was also seen in the DX and paired CR1 DEG profiling, reiterating their potentiality for MRD monitoring in AML-NK patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.